Cancer of the Ovary: There Is Reason for Optimism!

Journal of Obstetrics and Gynaecology Canada

Volumn 31, Issue 4, 2009, Pages 297-299

  Faught, Wylam ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN; PACLITAXEL; PLATINUM COMPLEX; BIOLOGICAL MARKER;

CANADA; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SCREENING; CYTOREDUCTIVE SURGERY; EARLY DIAGNOSIS; EDITORIAL; HEALTH EDUCATION; HUMAN; MEDICAL INFORMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; OVARY CARCINOMA; PROTEOMICS; RANDOMIZED CONTROLLED TRIAL (TOPIC); TRANSVAGINAL ECHOGRAPHY; ARTICLE; BLOOD; DIAGNOSTIC IMAGING; FEMALE; MASS SCREENING; MORTALITY; OVARY TUMOR;

BIOLOGICAL MARKERS; CA-125 ANTIGEN; DIAGNOSTIC IMAGING; FEMALE; HEALTH EDUCATION; HUMANS; MASS SCREENING; OVARIAN NEOPLASMS;

EID: 68049085550     PISSN: 17012163     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1701-2163(16)34142-1     Document Type: Editorial

References (16)

1. Canadian Cancer Society Canadian Cancer Statistics 2008, (ISSN 0835-2976). Available at:, Accessed February 5, 2009. http://www.cancer.ca.
2. Ozols R.F., Rubin S.C., Thomas G.M., Robboy S.J. Epithelial ovarian cancer. Principles and Practice of Gynecologic Oncology 2005, 895-987. Lippincott Williams & Wilkins, Philadelphia. 4th ed. W.J. Hoskins, C.A. Perez, R. Young, R. Barakat, M. Markman (Eds.).
3. Jacobs I.J., Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004, 3:355-366.
4. Markman J. The remarkable "paclitaxel story": how many chapters remain to be written?. Gynecol Oncol 2008, 111(1):7-8.
5. Ovarian Cancer Canada Seeds of Hope [newsletter] Fall/Winter 2008, Available at:, Accessed February 5, 2009. http://www.ovariancanada.org/index.asp?navid=27.
6. Andersen M.R., Goff B.A., Lowe K.A., Scholler N., Bergan L., Dresher C.W., Paley P., Urgan N. Combining a symptoms index with CA 125 to improve detection of ovarian cancer. Cancer 2008, 113(3):484-489.
7. Annunziata C.M., Azad N., Dhamoon A.S., Whiteley G., Kohn E.C. Ovarian cancer in the proteomics era. Int J Gynecol Cancer 2008, 18(Suppl. 1):1-6.
8. Hellstrom I., Raycraft J., Hayden-Ledbetter M., Ledbetter J.A., Schummer M., McIntosh M., et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003, 63:3695-3700.
9. Moore R.G., Brown A.K., Miller C.M., Skates S., Allard W.J., Verch T., et al. The use of multiple novel serum tumor markers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol 2008, 108(2):402-408.
10. Spencer J.A., Forstner R., Hricak H. Investigating women with suspected ovarian cancer. Gynecol Oncol 2008, 108(2):262-264.
11. Morgante G., la Marca A., Ditto A., De Leo V. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. Br J Obstet Gynaecol 1999, 106(6):524-527.
12. Le T., Al Fayadh R., Menard C., Hicks-Boucher W., Faught W., Hopkins L., et al. Variations in ultrasound reporting on patients referred for investigation of ovarian masses. J Obstet Gynaecol Can 2008, 30:902-906.
13. Elit L., Oliver T.K., Covens A., Kwon J., Fung-Kee-Fung M., Hirte H.W., on behalf of the Cancer Care Ontario Program in Evidence-based Care's Gynecology Cancer Disease Site Group, et al. Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer. A systemic review with metaanalyses. Cancer 2007, 109(4):692-702.
14. Kehoe S., Powell J., Wilson S., Woodman C. The influence of the operating surgeon's specialization on patient survival in ovarian carcinoma. Br J Cancer 1994, 70(5):1014-1017.
15. Zivanovic O., Eisenhauer E.L., Zhou Q., Iasonos A., Sabbatini P., Sonoda Y., et al. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 2008, 108:287-292.
16. Vergote I. Results of the EORTC-GCG/NCIC-CTG randomized trial comparing primary debulking vs neo-adjuvant chemotherapy in stage IIIC-IV ovarian, fallopian and peritoneal cancer (OVCA) October 2008.